Sumitomo Dainippon Enters Neurology Partnership with Otsuka Pharmaceuticals for US$890 M

By Swati Sharan

Pharma Deals Review: Vol 2022 Issue 1 (Table of Contents)

Published: 8 Jan-2022

DOI: 10.3833/pdr.v2022.i1.2653     ISSN: 1756-7874

Section: Research & Development



In a bid to broaden its neurology franchise, Sunovion Pharmaceuticals, a subsidiary of Sumitomo Dainippon has entered into a global collaboration and license agreement with Otsuka Pharmaceuticals to develop and commercialise four psychiatry and neurology compounds...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details